Basic VALSARTAN is Officially Generic !!!!

[Anonymous]

Monday, 14 February 2011

From Philippe de Jong (Altius, Brussels) comes details of a fascinating recent decision from the Antwerp Court of Appeal in a case concerning SPCs for combination products. The case is Novartis v Teva, case 2010/RK/456, decided on 9 February 2011. Explains Philippe:

"The Antwerp Court of Appeal ordered Teva not to launch prematurely a generic version of Novartis’ blockbuster drug Co-Diovan. The product which Teva intended to launch on 12 February 2011 – the expiry date of Novartis’ basic patent for valsartan (EP 443 983 B1) – contained, like Co-Diovan, valsartan and hydrochlorothiazide or ‘HCTZ’ as its active ingredients. However, this combination of valsartan and HCTZ is protected until 25 September 2012 by a Belgian SPC.
Teva launched a nullity action against this SPC before the Antwerp Commercial Court and also contested its prima facie validity in the summary proceedings which Novartis subsequently brought against Teva.
The main argument raised by Teva in support of its nullity allegations was that the product valsartan+HCTZ was not protected by the basic patent within the meaning of Article 3(a) of SPC Regulation 469/2009 because the combination of valsartan and HCTZ was not specifically disclosed in the claims of the basic patent.

 

[Anonymous]

Reads to me that they cannot launch unit 2012. Did u read your post?

 

[Anonymous]

Reads to me that they cannot launch unit 2012. Did u read your post?

"The product which Teva intended to launch on 12 February 2011 – the expiry date of Novartis’ basic patent for valsartan (EP 443 983 B1)"

They were blocked for HCT . Teva will lauch plain Valsartan soon
they can give a diuretic away for free

 

[Anonymous]

Maybe thats why there is such a sense of urgency so early in the year.

 

[Anonymous]

Just legal wrangling. Insurance companies don't care if diuretic included or not. Give it 6 mos and any rep/dm/md is 100% fucked!
And tekturkey franchise is just a few months behind once cash flow ain't so comfy anymore. Enjoy your career here

 

[Anonymous]

No, teva tried to use the diovan hct patent to void the diovan plan patent. They are about the 10th company that has tried this. The court said that diovan goes generic in 2012.

You will know when its about to go generic because we will no long have a job at nvs.

 

[Anonymous]

Why is this coming from a court in Belgium and not US court. Most at risk launches that are in the courts are in the US courts. Could this involve only Diovan in Europe??

 

[Anonymous]

Valsartan is basically worthless and always has been..we lied to everyone about the efficacy and slandered a perfectly good ARB! Look at all of our studies, they were riddled with falsehoods, lies and lack of efficacy and in fact in some did more harm than good! VALUE was certainly of no value, VaL-HF was a failure with others and now NAVIGATOR was a failure for two medicines of ours! The FDA if they had any balls should make us go around and apologize to every physician for the lies we told over the years! However we did a great marketing job paying docs to come to our programs and paying the high prescribers to speak even if nobody wanted to listen! Merck was always too stupid to figure that one out!

 

[Anonymous]

Valsartan is basically worthless .......The FDA if they had any balls should make us go around and apologize to every physician for the lies we told over the years! However we did a great marketing job paying docs to come to our programs and paying the high prescribers to speak even if nobody wanted to listen! Merck was always too stupid to figure that one out!

Merck was busy paying on other drugs & as it was it STILL took like what, 5 years ? for novarts to catch cozaar !
Novartis is barely ahead of DS ,if at all, on the scale of 3rd rate pharma co's

 

[Anonymous]

Valsartan is basically worthless and always has been..we lied to everyone about the efficacy and slandered a perfectly good ARB! Look at all of our studies, they were riddled with falsehoods, lies and lack of efficacy and in fact in some did more harm than good! VALUE was certainly of no value, VaL-HF was a failure with others and now NAVIGATOR was a failure for two medicines of ours! The FDA if they had any balls should make us go around and apologize to every physician for the lies we told over the years! However we did a great marketing job paying docs to come to our programs and paying the high prescribers to speak even if nobody wanted to listen! Merck was always too stupid to figure that one out!

Yup. A bunch of stiff yahoo's who have no ability for independent thought.

 

[Anonymous]

The way we filed Diovan patents globally means different countries have different patent dates of issue and therefore different dates of expiration. In fact in some countries in the emerging markets we have no formal patent and grow branded diovan along side generic valsartan. The world is much bigger than the USA so make sure you take a bit of time to read and study before making too many comments.